Japan Kidney Cancer Market Insight
Published: 30 May 2026 | Report Format: Electronic (PDF)
Japan’s market share for kidney cancer is on an upward trend with a CAGR of 7.37%, attributed to the rising number of cases of renal cell carcinoma, the aging of the Japanese population, and the increased uptake of targeted therapy drugs.
Japan Kidney Cancer Market Insights Forecasts to 2035
- The Japan Kidney Cancer Market Size Was Estimated at USD 744.5 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.37 % from 2025 to 2035
- The Japan Kidney Cancer Market Size is Expected to Reach USD 1515.5 Million by 2035
Notable Insights for Japan Kidney Cancer Market
- According to the type of cancer, renal cell carcinoma represented around 82-85% of the Japan kidney cancer market in 2025 due to increasing incidence rates, increased awareness concerning early cancer diagnosis, and advanced targeted therapy options available in the country.
- With respect to the type of treatment, targeted therapy accounted for about 44-47% of the Japan kidney cancer market in 2025. This is attributed to the rise in the preference for VEGF inhibitors, tyrosine kinase inhibitors, and precision oncology.
- The Ministry of Health, Labour, and Welfare in Japan has promoted the use of innovative treatments and precision medicine approaches to treat cancer patients. This has been one of the reasons behind the rapid uptake of treatment options for kidney cancer in Japan.
- Rise in investments made in immunotherapy, diagnosis through artificial intelligence, biomarker treatments, and precision oncology could aid in the development of the Japan kidney cancer market.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
- AI-Powered Oncology Intelligence and Industry Insights
Decisions Advisors delivers AI-powered market intelligence, kidney cancer industry analysis, competitive benchmarking, emerging precision oncology trends, and actionable business insights to help organizations identify growth opportunities and make data-driven strategic decisions in the Japan kidney cancer market.
- Advanced Cancer Therapeutics Research Methodologies and Accurate Market Forecast Analysis
Our research combines primary and secondary research methodologies, expert interviews, proprietary analytical models, and data triangulation techniques to provide accurate kidney cancer market size estimation, CAGR analysis, oncology treatment demand forecasting, and reliable healthcare industry intelligence.
- Comprehensive Precision Oncology Competitive Landscape and Growth Opportunity Analysis
We provide in-depth analysis of kidney cancer market dynamics, immunotherapy advancements, targeted treatment trends, consumer behaviour patterns, competitive landscape evaluation, and investment opportunities across the Japan oncology and cancer therapeutics industry.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Kidney Cancer market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment Market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the Market.
Top Companies in Japan Kidney Cancer Market
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Eisai Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Ono Pharmaceutical Co., Ltd.
- Exelixis, Inc.
- AstraZeneca PLC
- Other
Recent Developments:
- In October 2025, major pharmaceutical companies in Japan increased investments in combination immunotherapy and biomarker-driven kidney cancer treatment solutions to improve patient survival rates and precision oncology outcomes.
Market Segmentation:
Japan Kidney Cancer Market, By Cancer Type
- Renal Cell Carcinoma
- Transitional Cell Carcinoma
- Wilms Tumor
- Others
Japan Kidney Cancer Market, By Treatment Type
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Radiation Therapy
- Surgery
Japan Kidney Cancer Market, By End User
- Hospitals
- Cancer Research Institutes
- Specialty Clinics
- Others
Expert Views:
The Japan kidney cancer market is expected to witness substantial growth in the coming years owing to increasing prevalence of renal cancers, rising adoption of targeted and immunotherapy treatments, advancements in precision oncology technologies, and growing investments in cancer research and diagnostics. Moreover, expansion of AI-powered cancer diagnostics and biomarker-driven treatment strategies is expected to provide ample growth opportunities for market players in Japan.
Author: Aditi and Govind By Spherical Insights and Consulting